ArticleNature2023
Targeting of intracellular oncoproteins with peptide-centric CARs.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
15.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 66 citations in OpenAlex.
- Article
- Paediatric therapeutic development workshop on desmoplastic small round cell tumours.British journal of cancer · 2026Review
- Multi-dimensional orchestration of binders for improved CAR-T immunotherapy.Cancer letters · 2026Review
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- MHCXGraph: a graph-based approach to detecting T-cell receptor cross-reactivity.Briefings in bioinformatics · 2026Article
- Intracellular protein binders for imaging, control and future therapeutics.Nature biomedical engineering · 2026Review
- HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy.Signal transduction and targeted therapy · 2026Article
- Computational prediction of TCR cross-reactivity: principles, challenges and translational opportunities.Journal of translational medicine · 2026Review
- The evolution of display technologies for antibody drug discovery.Trends in biotechnology · 2026Review
- A generalizable system for antigenic peptide targeting across HLA-I allotypes.bioRxiv : the preprint server for biology · 2026Article
- Advances in targeted therapies for pediatric tumors.Acta pharmacologica Sinica · 2026Article
- Integrated in silico-in vitro identification of high-affinity TCR-Like antibodies targeting HPV18 E6/E7 for cervical cancer detection.Archives of virology · 2026Article
- AI-enabled virtual immunopeptidomics links quantitative neoantigen presentation to immunogenicity.bioRxiv : the preprint server for biology · 2026Article
- The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology · 2026Review
- The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer.iScience · 2026Article
- Cell therapy for brain tumors: The first 60 years.Cell reports. Medicine · 2026Review
- Lactylation-related gene signature as a prognostic biomarker for neuroblastoma: insights into tumor progression and immune modulation.Cell & bioscience · 2026Article
- CAR T cells: the missing piece needed to improve outcomes for children with cancer?Journal for immunotherapy of cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 5 institutions in 2 countries.
Mark YarmarkovichPerlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA. mark.yarmarkovich@nyulangone.org.
Quinlen F MarshallDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-4736-9716
John M WarringtonDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0001-6066-5491
Rasika PremaratneMyrio Tx, Melbourne, Victoria, Australia.
Alvin FarrelDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0003-1087-9840
David GroffDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0001-6897-2656
Wei LiUniversity of Pittsburgh, Pittsburgh, PA, USA.
Moreno di MarcoUniversity of Tubingen, Tubingen, Germany.
Erin RunbeckDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Hau TruongPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Jugmohit S ToorDepartment of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA, USA.
Sarvind TripathiDepartment of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA, USA.ORCID 0000-0002-6959-0577
Son NguyenMassachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-0475-5158
Helena ShenDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-0500-441X
Tiffany NoelDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nicole L ChurchMyrio Tx, Melbourne, Victoria, Australia.
Amber WeinerDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nathan KendserskyDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0003-0132-8748
Dan MartinezDepartment of Pathology and Lab Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rebecca WeisbergDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Molly ChristieDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Laurence EisenlohrDepartment of Pathology and Lab Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Kristopher R BosseDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Dimiter S DimitrovUniversity of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-2258-1024
Stefan StevanovicUniversity of Tubingen, Tubingen, Germany.
Nikolaos G SgourakisPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Ben R KiefelMyrio Tx, Melbourne, Victoria, Australia.
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. maris@chop.edu.ORCID 0000-0002-8088-7929
Children's Hospital of Philadelphia · USUniversity of California, Santa Cruz · USUniversity of Pittsburgh · USUniversity of Tübingen · DEMassachusetts Institute of Technology · US
Funding
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MDiscovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7MAn integrative structural biology approach to understanding metabolite recognition by cellular receptorsR35GM125034 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SGOURAKIS, NIKOLAOS · 2017 to 2025
$4.7MMolecular mechanism of antigen editing by Class-I MHC ChaperonesR01AI143997 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SGOURAKIS, NIKOLAOS · 2019 to 2023
$4.0MNCI NIH HHS R35 CA220500NCI NIH HHS U54 CA232568NIAID NIH HHS R01 AI143997NIGMS NIH HHS R35 GM125034
Abstract
The majority of oncogenic drivers are intracellular proteins, constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes
Indexed as
Antigens, NeoplasmNeuroblastomaOncogene ProteinsPeptidesReceptors, Chimeric AntigenAfricaAllelesAmino Acid SequenceAnimalsCarcinogenesisCross ReactionsHLA-A AntigensHomeodomain ProteinsHumansMiceTranscription FactorsAntigens, NeoplasmHLA-A AntigensHomeodomain ProteinsNBPhox proteinOncogene ProteinsPeptidesReceptors, Chimeric AntigenTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.